Antibody engineering for the development of therapeutic antibodies.
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.
Kim
Sang Jick
SJ
Laboratory of Antibody Engineering, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Korea.
Park
Youngwoo
Y
Hong
Hyo Jeong
HJ
D000818:Animals; D000906:Antibodies / Q000737:chemistry* / Q000502:physiology; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000915:Antibody Affinity; D006801:Humans; D051379:Mice; D008958:Models, Molecular; D010599:Pharmacokinetics; D015202:Protein Engineering / Q000379:methods*; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D013678:Technology, Pharmaceutical
D000906:Antibodies; D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins